Skip to content

Clinical study on Mformulae Acne Barrier Ritual and Mformulae Calming Matte on healthy participants with dry and sensitive skin.

Evaluation of Efficacy and Safety of Mformulae Acne Barrier Ritual and Mformulae Calming Matte for skin barrier repair in healthy participants with dry and sensitive skin. - An open label, non-comparative, interventional, prospective, clinical study - NIL

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/01/100866
Enrollment
50
Registered
2026-01-12
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L853- Xerosis cutis Health Condition 2: R21- Rash and other nonspecific skin eruption

Interventions

Intervention1: Mformulae Calming Matte and Mformulae Acne Barrier Ritual: Subjects will be asked to apply Mformulae Calming Matte all over the face during day time(after bath) and Mformulae Acne Barri

Sponsors

MJ-Cos Sciences Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects having mild to moderate skin dryness and any one of the skin conditions i.e. irritation, erythema, swelling, and itching (assessed using clinical grading score) due to skin currently on retinoid treatment, reactive rosacea-prone (currently calm skin), atopy-prone (currently calm skin but has a history of easy flaring), skin currently on benzoyl peroxide treatment for acne, acne-prone/oily with dehydrated combination skin, post-procedure skin (7 to 14 days after chemical peel or microneedling treatment), post-procedure laser skin treatment (5 to 7 days after the treatment). 2. Willing to comply with all requirements of the study.

Exclusion criteria

Exclusion criteria: 1. Subjects with a known current history of chronic skin diseases or autoimmune diseases, such as atopic dermatitis, psoriasis, chronic urticaria, vitiligo and rosacea 2. Subjects with a tattoo, a scar, moles, too many hairs or anything on the Right leg which might interfere with the evaluation. 3. Subjects with intensive exposure to sunlight or UV-rays within the previous month and foreseen during the study. 4. Subjects who have used facial blemish-lightening products (such as products claiming to have whitening or blemish-lightening effects), topical or oral whitening drugs. Moisturizing cream, lotion or oil within 21 days before entering the trial 5. Subjects on any other investigational products within 1 month prior to randomization 6. Subjects with known current tuberculosis, HIV, ischemic heart disease, cancer, kidney failure, liver failure 7. Pregnant and lactating women 8. Known hypersensitivity to any of the ingredients of Mformulae Acne Barrier Ritual and Mformulae Calming Matte 9. Other conditions, which in the opinion of the investigators, make patient unsuitable for enrolment or could interfere with his/her participation in, and completion of the study

Design outcomes

Primary

MeasureTime frame
1. Change in investigator-assessed skin irritation, erythema, swelling, and itching 2. Change in skin cutaneous moisturization or skin dryness Timepoint: Baseline visit, 5 mins after application of product, day 15 and day 30

Secondary

MeasureTime frame
1 Change in water content or hydration of the skin surface as assessed using Corneometer 2 Change in Trans epidermal water loss as assessed using Tewameter 3 Change in calming or soothing effect 4 Acceptance of scent or aroma as assessed using graded scale 5 Changes in blemishes on skin 6 Skin patch test using Dermal Response Score. 7 Difference in number of comedones i.e. blackheads and whiteheads on the face and body 8 Assessment of ability of Mformulae Acne Barrier Ritual and Mformulae Calming Matte to absorb into the skin 9 Assessment of oily or greasy appearance of skin after application of study products 10 Assessment of feeling of oil on skin 11 Global assessment of overall change by participants and physician 12 Assessment of post treatment tolerability of study drug by participants and physician. 13 Assessment of adverse events, adverse drug reactions including vitals Timepoint: Baseline visit, 5 mins after application of product, day 15 and day 30

Countries

India

Contacts

Public ContactDr Sanjay Tamoli

Target Institute of Medical Education and Research Pvt Ltd

targetinstitute@yahoo.com9322522252

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026